[Carbohydrate metabolism in bezafibrate therapy. Controlled study of glibenclamide-treated diabetics with hyperlipidemia].
D000368:Aged; D001629:Bezafibrate; D050260:Carbohydrate Metabolism; D002986:Clinical Trials as Topic; D002994:Clofibrate / Q000031:analogs & derivatives*; D002995:Clofibric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000188:drug therapy*; D005905:Glyburide / Q000627:therapeutic use*; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008875:Middle Aged; D010349:Patient Compliance
D000960:Hypolipidemic Agents; D002995:Clofibric Acid; D002994:Clofibrate; D005905:Glyburide; D001629:Bezafibrate
Kohlenhydratstoff-wechsel unter Bezafibrat-Therapie. Kontrollierte Studie bei Glibenclamid-behandelten Diabetikern mit Hyperlipidämie.